# Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1

> **NCT06630286** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Gilead Sciences** · enrollment: 609 (actual)

## Conditions studied

- HIV-1-infection

## Interventions

- **DRUG:** ISL/LEN
- **DRUG:** B/F/TAF
- **DRUG:** PTM B/F/TAF
- **DRUG:** PTM ISL/LEN

## Key facts

- **NCT ID:** NCT06630286
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-10-09
- **Primary completion:** 2026-04-17
- **Final completion:** 2030-08
- **Target enrollment:** 609 (ACTUAL)
- **Last updated:** 2026-04-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06630286

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06630286, "Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06630286. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*